

## REFERENCES

- Abo Farsakh H, Berry PL, Hill LL et al.*: Mesangial IgG Deposits in childhood minimal change disease; Clinical relevance. Clin Nephrol. 1993;39: 245-248.
- Abramson Sb, Leszczynska-Piziak J, Weiss-mann G*: Arachidonic acid a second messenger: Interactions with a GTP - binding protein of human neutrophils. J Immunol. 1991;147: 231-236.
- Albrightson CR, Short B, Dytko G, Zabko-Potapovich B, Brickson B, Adams JL, Griswold DE*: Selective inhibition of 5-lipoxygenase attenuates glomerulonephritis in the rat. Kidney Int. 1994; 45: 1301-1310.
- Alpers CE, Hudkins KL, Pritzl P, Johnson RJ.*: Mechanisms of clearance of immune complexes from peritubular capillaries in the rat. Am J Pathol. 1991;139: 855-867.
- Appel GB, Blum CB and Chien S*: The hyperlipidaemia and the NS relationship to plasma albumin concentration, oncotic pressure and viscosity. New Eng J Med. 1985; 312: 1544.
- Arbeitsgemeinschaft Fur pediatrische Nephrologie*: Cyclophosphamide treatment of steroid dependent NS; Comparison of eight weeks with twelve weeks course. Arch Dis Child. 1987;62: 1102.
-

- Armitage P and Berry G:** Statistical methods in medical research 3<sup>rd</sup> edition. Ganin (eds) Blackwell Scientific Publication, Oxford. 1994; 1-1061.
- Aso T, Shilatitard A, Conaway JW. Conaway RC.:** Transcription syndromes and the role of RNA polyemrase II general transcription factors in human disease. J Clin Invest. 1996; 97: 1561-1569.
- Atkins RC and Holdsworth SR:** Cellular neck of immune glomerular injury. Contemporary Issues in Nephrology.1988;18: 111-135.
- Badr KF, DeBoer DK, Schwartzberg M, Serhan CN:** Lipoxin A<sub>4</sub> antagonize cellular and in vivo actions of leukotriene D<sub>4</sub> in rat glomerular mesangial cells; evidence for competition at a common receptor. Proc Natl Acad Sci USA. 1989;86: 3438-3442.
- Badr KF.:** Five-lipoxygenase products in glomerular immune injury. J Am Soc Nephrol. 1992; 3: 907-915.
- Badr KF.:** Glomerulonephritis; Roles for lipoxygenase pathways in pathophysiology and therapy. Curr Opin Hypertens Nephrol.1997;6: 111-118.
- Badr KF:** Arachidonic acid metabolites in glomerular injury. Semin Nephrol, 1991; 11: 332-339.

- Bagga A, Scharma A, Srivastava RN:** Levamisole therapy in steroid dependent NS. *Ped Nephro.* 1997;111: 418-420.
- Bakker WW and Van Luijk WHJ:** Do circulation factors play a role in the pathogenesis of minimal change NS. *Ped Nephrol.* 1989; 3: 341-349.
- Bakr A and El-Shenawy F:** HLA DQB<sub>1</sub> and DRB<sub>1</sub>, alleles in Egyptian children with steroid sensitive NS. *Ped Nephrol.* 1998;12: 234-237.
- Barnes PJ, Chung KF, Page CP:** Inflammatory mediators and asthma. *Pharmacol Rev.* 1988;40: 49-84.
- Barrat TM, Beattie JM, Coleman J et al.:** Consensus statement on management and audit potential for SRNS. *Arch Dis Child.* 1994;70: 151.
- Bazzoni G Dejana E, del Maschia A,:** Platelet-dependent modulation of neutrophil function. *Pharmacol Res.* 1992; 26: 269-272.
- Belch JJF, Madhok AR, O'Dowd A, Sturrock RD:** Effects of altering dietary essential fatty acids on requirements for nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis: A double blind placebo controlled study. *Ann Rheum Dis.* 1988;47: 97.
- Bentley DR:** The Human Genome Project-an overview. *Med Res Rev.* 2000; 3: 189-196. Review.

- Bergstein JM:** Conditions particularly associated with proteinuria. In: Nelson WE, Behrman RE, Kleigman Rmand Arvin AM (eds.). Nelson Textbook of peiatrics (15<sup>th</sup> ed).WB Saunders Company, philadelphia, London. Montreal, Sydnny, Tokyo. 1996 ;1668-1718.
- Bhimma R, Coovadia HM, Adhiklari M:** Nephrotic syndrome in African children changing perspectives over 20 years. Ped Neph.1997; 11: 429-434.
- Bone RC:** Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome ). JAMA.1992;268: 3452-3455.
- Bonventre JV, Weber PC, Gronich JH.:** PAF and PDGF increase cytosolic ( $Ca^{2+}$ ) and phospholipase activity in mesangial cells.Am J Physiol. 1988;254: F87-F94.
- Bonventre JV.:** Phospholipase A<sub>2</sub> and signal transduction. J Am Soc Nephrol. 1992;3: 128-150.
- Brady HR, Persson U, Ballermann BJ, BM. Serhan CN.:** Leukotrienes stimulate neutrophil adhesion to mesangial cells; Modulation with lipoxins. Am J Physiol. 1990; 259: F809-F815.
- Brady HR, Serhan CN:** Adhesion promotes transcellular leukotriene biosynthesis during neutrophil – glomerular endothelial cell interactions; Inhibition by antibodies against CD<sub>18</sub> and L-

selectin. *Biochem Biophys Res Commun.* 1992; 186: 1307-1314.

**Brady HR, Serhan CN:** Lipoxins ; Putative barking singals in host defense, Inflammation and hypersensitivity. *Curr Opin Hyperten Nephrol.* 1996;5: 20-27.

**Brady HR. O'Meara YM:** Lipoxins, leucocyte recruitment and the resolution phase of acute glomerulonephritis. *Kideny Int.*1997; S 58: 56-61.

**British Association for Ped Nephro and Research Unit Royal Colleage of Physicians:** Consensus statement on management and audit potential for steroid responsive NS. *Arch Dis Child.*1994; 70: 151-157.

**Broyer M, Meyrier A, Niaudet P et al.:** Minimal change and focal segmental glomerulosclerosis. In *Oxford of Clinical Nephrology* (2<sup>th</sup>ed): Vol 1, Jay Bernstein (eds) Oxford , New York, Tokyo. 1998; 493-539.

**Broyer M, Meyrier A, Niaudet P, et al.:** Minimal changes and focal segmental glomerulosclerosis. In; Davison AM, Cameron S, Grunfield, JP, et al.eds, *Oxford Textbook of Clinical Nephrology*. 2<sup>nd</sup> ed. Oxford. Oxford University Press.1997; 493-536.

**Buston C, Gonzalez E, Muley R, Alonso JL, and Egido J.:** Increase of tumour necrosis factor alpha synthesis and gene expression

in peripheral blood mononuclear cells of children with idiopathic nephrotic syndrome. *European Journal of Clinical Investigation*. 1994; 24: 799-805.

**Calhoun WJ, Lavins BJ, Glass M.:** Effect of Accolate (Zafirlukast) on bronchoalveolar lavage fluid (BAL) after semgental antigen bronchoprovocation (SBP) in patients with mild to moderate asthma [ abstract ]. *Am J Respir Crit Care Med*. 1995; 151: A42.

**Cameron JS:** Platelets in glomerular dis. *Annu Rev Med*. 1984; 35: 175-180.

**Cameron JS:** The engima of focal segmental glomerulosclerosis. *Kid Int*. 1996; 50: S 119-S 131.

**Chan MK, Chan KW, and Jones B.:** Immunoglobulins (1gG, 1gM, 1gA, 1gE) and complement components (C<sub>3</sub>, C<sub>4</sub> )in nephrotic syndrome due to minimal change and other forms of glomerulonephritis; A Clue for stroid therapy?. *Nephron*. 1987 ; 47: 125.

**Choy B, Green MR.:** Eukaryotic activators function during multiple steps of preinitiation compex assembly. *Nature*. 1993; 366: 531-536.

**Christodoulou J.:** Genetic defects causing mitochondrial respiratory chain disorders and disease. *Hum Reprod*. 2000 ;15: 28-43. Review.

- Condon, C., Squires, C., and Squires, C.L.:*** Control of rRNA transcription in *E. coli* Microbiol. Rev. 1995; 59: 623-645.
- Congoli I, Tabacchi P, Pasquali S, et al.:*** B-cell subset alterations in idiopathic glomerulonephritis. Clinical and experimental immunol. 1982; 50: 70-76.
- Connor M, Ferguson –Smith M.:*** Medical genetics. 5<sup>th</sup> ed. Blackwell Science, USA 1997.
- Corado J, Le Deist F, Griscelli C, et al.:*** Inositol 1, 4, 5-trisphosphate and arachidonic acid–induced calcium mobilization in T and B lymphocytes. Cell Immunol. 1990; 126: 245-254
- Cortes L and Tejani A:*** Dilemma of FSGS & MCNS. Kid Internat. 1996; 49: S 57-S 63.
- Couser WG, Abrass CK:*** Pathogenesis of membranous nephropathy. Ann Rev Med. 1988 ;39: 517-530.
- Couser WG, and Salant D.J:*** Immunopathogenesis of glomerular capillary wall injury in nephrotic states. Contemp Issues Nephrol. 1982 ; 9: 47-83.
- Couser WG, Ochi RF, Baker PJ, and Johnson RJ:*** Depletion of C<sub>6</sub> reduces proteinuria in a model of membranous nephropathy induced with a non glomerular antigen. J Am Soc Nephrol. 1991; 2: 894-901.
- Crawford M:*** The genetics of renal tract disorders. Oxford University Press, London. 1988.

- Cromwell O:** Mediators in allergen-induced asthma. Bailliere's Clinical Immunology and Allergy. 1988; 2: 197-216.
- Curr M1 and Harwood JL:** Lipid Biochemistry textbook. Campman & Hall. London, New york, Tokyo, Melbourne, Madras. 1991; Ch<sub>3</sub>.
- D'Amico G and Ferrario F:** Mesangiocapillary glomerulonephritis. J Am Soc Nephrol. 1993 ; 2: S 159.
- Daniel PS and Abba IT,:** Basic Human Immunology textbook. Prentice-hall International Inc. (Publ). 1991;155-157.
- Daniel V, Trautmann Y, Konrad M, et al. :**  $\beta$ - lymphocyte populations, cytokines, and other growth factor in serum and urine of children with idiopathic nephrotic syndrome. Clin Nephrol. 1997; 47: 289-297.
- Dantal J, Bigot E, Bogers W et al.:** Effect of plasma protein adsorption on protein excretion in kidney transplant recipients with recurrent NS. N Engl J Med. 1994 ;330: 7-14.
- Davenport A, Maciver AG and Hall CL:** Do mesangial immune complex deposits affect the renal prognosis in membranous glomerulonephritis.Clin Nephrol.1994 ; 41: 176.
- Diamant Z, Timmers MC, Van der Veen H, et al.,:** The effect of MK – 0591, a novel 5 – lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen induced airway

responses in asthmatic subjects in vivo. J Allergy Clin Immunol. 1995; 95: 42-51.

**Doll' Aglio P, Chizzolini C, and Brigati C.:** Minimal change glomerulonephritis and focal glomerulosclerosis markers, an in vitro activity of peripheral blood mononuclear cells. proceeding of the European Dialysis and Transplant Association. 1982 ;19: 673-678.

**Donadio JV, Bergsteal EJ, Offord KP, et al.:** A controlled trial of fish oil in IgA nephropathy. N Engl J Med. 1994; 331: 1194-1199.

**Drumond MC, Kristal B, Myers BD, et al.:** Structural Basis for reduced glomerular filtration capacity in nephrotic humans. J Clin. 1994 ;94: 1187.

**El-Zouki AY, Amin F and Jaiswal OP,:** Primary NS, in Arab children. Arch Dis Child. 1984;59-253.

**El-Zouki AY:** Immunological aspects of primary nephrotic syndrome in childhood. Saudi J Kidney Dis Transplant. 1994 ;5: 483.

**Errington, J. B.:** subtilis sporulation: regulation of gene expression and control of morphogenesis. Microbiol Rev. 1993; 57: 1-33.

**Evans JF, Dupuis P, Ford- Huchinson AW:** Purification and characterization of leukotriene A<sub>4</sub> hydrolase from rat neutrophils Biochim Biophys Acta. 1985; 840; 43-50.

- Fahrer AM, Bazan JF, Papathanasiou P, Nelms KA, Goodnow CC.:** A genomic view of immunology. *Nature*. 2001 ;409: 832-838.
- Fauler J , Wienneyer A, Marx KH, Kühn K, Koch KM, Frolich JC.:** LTB<sub>4</sub> in nephrotoxic serum nephritis in rats. *Kidney Int*. 1989;36: 46-50.
- Feinmark SJ.:** Cooperative synthesis of leukotrienes by leukocytes and vascular cells. *Ann N Y Acad Sci*. 1988;524: 122-132.
- Felsenfeld, G.:** Chromatin as an essential part of the transcriptional mechanism. *Nature*. 1992; 355: 219-224.
- Firth JD and Ledingham JG:** Effect of naturetic agents of the inhibition of Na metabolism and handling in isolated perfused kidney in nephrotic rat. *Clin Sci*. 1990 ;79: 559-574.
- Fischer DB, Christman JW, Badr KF:** Fifteen-S-hydroxyeicosatetraenoic acid (15-S-HETE) specifically antagonizes the chemotactic action and glomerular synthesis of leukotriene B<sub>4</sub> in the rat. *Kidney Int*. 1992;41: 1155-1160.
- Fisher D, Takahasi K, Ebert J, Badr KF.:** Limited early therapy with a novel 5- liopxygenase activating protein antagonist MK-886, during heterologous rat nephrotoxic serum nephritis totally prevents proteinuria in the autologous phase (Abstract). *J Am Soc Nephrol*. 1990; 1:628.

- Freeman BA, Lynn WS:** Fatty acid secretion and metabolism in “activated” rabbit alveolar macrophages. *Biochim Biophys Acta*.1980; 620: 528-537.
- Ganin EH, West L, Zheng W:** Effect of cytokine on glomerular sulfated compounds and albuminuria. *Ped Nephrol*. 1997 ;11: 274-279.
- Garcia -Estan J, Roman RJ, Lianos EA, Garancis J:** Effects of complement depletion on glomerular eicosanoid production and renal hemo-dynamics in rat nephrotoxic serum nephritis. *J Lab Clin Med*. 1989;114: 389-393.
- Garrick R, Goodman A, Shen ST, Ogune S, Wong PY:** Regulation of lipoxins and leukotriene B<sub>4</sub> production in rat mesangial cells. *Adv Prostaglandin Thromboxane Leukot Res*. 1991;21: 701-706.
- Geoffrey Z:** Biochemistry textbook. Mecomilian publishing Company. New York and collier Macmilian Publishers London. 1988; 22: 4-720.
- Gilchrist D, Glerum DM, Wevrick R.:** Deconstructing Mendel; new aspects in genetic mechanisms. *Clin Invest Med*. 2000; 3: 188-98. Review.
- Glass CK, Rose DW, Rosenfeld MG.:** Nuclear receptor coactivators. *Curr Opin Cell Biol*. 1997; 9: 222-232.

- Glasscock RJ, Adler SF, Ward HF et al.:** Primary glomerular diseases In Brenner BM (ed). The kid (4<sup>th</sup>ed.)WB Saunders Company, Philadelphia, London, Toronto, Montreal, Sydney, Tokyo. 1991;112-1203.
- Glasscock RJ, Cohen AH, and Alder SG:** Primary glomerular disease: in Brenner BM (ed, ). The kidney (5<sup>th</sup> ed.) WB Saunders Company, Philadelphia, London, Toronto, Montreal, Sydney, Tokyo. 1996; 30: 1423-1497.
- Gomez-Chiarri M, Ortiz A, Lerma JL:** Involvement of TNF and platelet activating factor in the pathogenesis of experimental nephritis in rats. Lab.1994; 70: 449-459.
- Graber, Sumida C, Nunez EA:** Fatty acids and cell signal transduction. J Lipid Mediat Cell Signal. 1994; 9:91-116.
- Grope WE:** Minimal change disease. Semin Nephro.1982 ;1 2: 241.
- Guasch A, Zayas CF, Badr KF.:** Mx- 591 acutely restores glomerular size selectivity and reduces proteinuria in human glomerulonephritis. kidney Int. 1999; 56 (1): 261-267.
- Hackshaw KV, Voekel NF, Thomas RB, Westcott JY.:** Urine leukotriene E<sub>4</sub> levels are elevated in patients with active systemic lupus erythematosus. J Rheumatol. 1992; 19: 252-258.
- Haeggstrom J, Radmark O, Fitzpatrick FA:** Leukotriene A<sub>4</sub> hydrolase activity in guinea pig and liver, Biochim Biophys Acta. 1985;835: 378-384.

- Hall JG.:** Human genetics: Chromosomal clinical abnormalities. In Behrman RE, Kligman RM, Arvin AM (eds.) Nelson textbook of pediatrics, 15<sup>th</sup> ed, 1. WB saunders, Philadelphia.1996; P 312.
- Hammad AM.:** Study of some immune aspects in primary nephrotic syndrome in children. A thesis for MD degree. Pediatric Department, Faculty of Medicine, Mansoura University. 1997.
- Hawkins D, Cochrane CG:** Glomerular basement membrane damage in immunological glomerulonephritis. Immunology.1968; 14: 665-674.
- Haws RM an Baum M:** Efficacy of albumin and diuretic therapy in children with NS. Pediatrics. 1993;91: 1142.
- Henderson WR.:** The role of leukotrienes in inflammation. Am Int Med. 1994;121: 684-697.
- Heslan JM, Lautie JP, Intrator L, Blane C, Lagrue G and Sobel AT.:** Impaired IgA synthesis in patients with the nephrotic syndrome. Clinical Nephrology. 1982;18: 144-147.
- Heslan JMJ, Branellec AI, pilatte Y, et al.:** Differentiation between vascular permeability factor and IL- 2 in lymphocyte supernatants from patients with minimal-change nephrotic syndrome. Clin Exp Immunol. 1991; 86: 154-162.

- Hill CS, Treisman R.:** Transcriptional Regulation by Extracellular Signals: Mechanisms and Specificity. *Cell*. 1995; 80: 199-211.
- Holley KE and Donadio JV:** Membranoproliferative glomerulonephritis. In Tisher CC and Brenner BM (eds). *Renal pathology: with clinical and foundational; correlations* (2<sup>th</sup> Ed.) JB Lippincott, Philadelphia. 1994;798-918.
- Horlein, A.J. et al.:** Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor corepressor. *Nature*. 1995; 377: 397-404.
- Hsieh C.S, Macatonia S.E Tripp C.S, Wolf S.F, Garra A.O, and Murphy K.M:** Development of Th<sub>1</sub> CD<sub>4</sub> T cells through IL<sub>12</sub> produced by listeria-induced macrphages. *Science*.1993; 260: 547.
- Humpherys MH:** Mechanisms and management of nephrotic edema. *kid Int*. 1994; 45: 266.
- International Study of Kidney Disease in Children:** Early identification of frequent relapsers among children with minimal change nephrotic syndrome. *J Pediatr*. 1982;101: 514-518.
- International Study of Kidney Disease in Children:** NS in children: prediction of histopathology from clinical and laboratory criteria of histopathology from clinical and laboratory criteria at time of diagnosis. *Kid Int*. 1978;13: 159.

- International Study of Kidney Disease in Children:*** The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to Prednisone. J pediatr. 1981; 98: 561-564.
- Izant, J.G. and Weintraub, H.:*** Inhibition of thymidine kinase gene expression by antisense RNA: a molecular approach to genetic analysis. Cell. 1984; 36: 1007-1015.
- Jayne DRW, Marshall PD, Jones SJ, Lokwood CH:*** Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kid Int. 1990;37: 965-970.
- Johnson R, Yamabe H, Chen YP, Gordon K, and Couser WG:*** Glomerular epithelial cell secrete a glomerular basement membrane degrading metalloprotein. J Am Soc Nephrol. 1992; 2: 1388-1397.
- Johnson RJ, Guggenheim S, Klebanoff SJ, et al.:*** Morphologic correlates of glomerular oxidant injury induced by the myeloperoxidase hydrogen peroxide-halide system of neutrophils. Lab Invest. 1988;58: 294-301.
- Johnson RJ, Lovett D, Leherer RI, Couser WG, Klebanoff J.:*** Role of oxidants and proteases in glomerular injury. Kidney Int. 1994; 45: 352-356.
- Johnson RJ, Raines EW, Floege J , et al.:*** Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in

- the rat by antibody to platelet-derived growth factor. *J Exp Med.* 1992;175: 1413-1418.
- Johnson RJ:** Platelets in inflammatory glomerular injury. *Semin Nephrol.* 1991;11: 276-284.
- Jongencel CV, Bouvier J, Bairoch A:** A unique signature identifies a family of zinc-dependent metallopeptidases. *FEBS Lett.* 1989;242: 211-214.
- Kamakaka, R.T., Bulger, M., and Kadonaga, J.T.:** Potentiation of RNA polymerase II transcription by CAL<sub>4</sub>, VP<sub>16</sub> during but not after DNA replication and chromatin assembly. *Genes Dev.* 1993; 7: 1779-1795.
- Kang J, Bai KM, Wang BL, et al.:** Increased production of Interleukin 4 in children with simple idiopathic nephrotic syndrome. *Clin med J Eng.* 1994;107: 347.
- Kanwar YS, Liu ZZ, Kashiara N, Wallner E:** Current status of the structural and functional basis of glomerular filtration and proteinuria. *Semin Nephrol.* 1991; 11: 39-413.
- Kato T, Lakkis FG, Makita N, Badr KF:** Co-regulated expression of glomerular 12/15-lipoxygenase and interleukin-4 mRNAs in rat nephrotoxic nephritis. *Kidney Int.* 1994;46: 341-349.
- Kaysen GA, Don B and Schmbelan M:** Proteinuria, albumin synthesis and hyperlipidaemia in NS. *Neph Dial Transplant.* 1991; 6: 141.

- Kaysen GA, Jones H, Martin V, et al.:** Low protein diet restricts protein synthesis in nephrotic rats. *J of Clinic Invest.* 1989;83: 1623-1629.
- Kaysen GA, Kirkpatrick WG, Covser WG, et al.:** Albumin homeostasis in the nephrotic rat; nutritional considerations. *Am J Physiol.* 1987; 247: 192.
- Kaysen GA:** Plasma composition in the NS. *Am J Nephrol.* 1993;13: 347.
- Kellaway CH, Trethenie QJ.:** Liberation of slow-reacting smooth muscle-stimulating substance in anaphylaxis. *Exp Physiol Cogn Med Sci.* 1940; 30: 121-145.
- Kerjaschki D:** The pathogenesis of membranous glomerulonephritis from morphology to molecules. *Virchows Arch B Cell Pathol.* 1990;58: 253-271.
- Kim EM, Striegel J, Kim Y, et al.:** Recurrence of steroid resist NS in kidney transplant is associated with increased acute renal failure. *Kid Int.* 1994;45: 1440-1450.
- Konard M, Mytiliness J, Ruder H, et al.:** HLA DR<sub>7</sub> predicts the response to alkylating agents in steroid sensitive NS. *Pediat Nephrol.* 1997;2: 11-16.
- Koskimies O:** Long-term outlook of primary NS. *Arch Dis Child.* 1982;57: 544.
- Kremer JM:** Effects of modulation of inflammatory and immune parameters in patients with rheumatic and inflammatory

disease receiving dietary supplementation of n-3 and n-6 fatty acids. *Lipids*. 1996;31: S253.

**Krensky AM, Ingelfinger JR, Grupe WE, et al.:** Peritonitis in childhood  
N S. Am J Dis Child. 1982; 36: 732.

**Laguer C, Branellec A, and Blae C.:** A vascular permeability factor in lymphocyte pharmacological and physicochemical properties. *Biomedicine*. 1975;23: 73-75.

**Lefkowitz JB, Nagamatsu T, Pippin J, Schreiner GF:** Role of leukocytes in metabolic and functional derangements of experimental glomerulonephritis. *Am J Physiol*. 1991;261: F213-F220.

**Lefkowitz JB, Pippin J, Nagamatsu T, Lee V.:** Urinary eicosanoids and assessment of glomerular inflammation. *J Am Soc Nephrol* 1992; 2: 1560-1567.

**Lewis MA, Baildom EM, Davis N, et al.:** NS from toddlers to twenties. *Lancet*. 1989;1: 255.

**Lewis RA, Austen KA:** The biologically active leukotrienes. Biosynthesis, metabolism, receptors, functions and pharmacology. *J Clin Invest*. 1984; 73: 889-897.

**Lewis RA, Austen KF, Soberman RJ.:** Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. *N Engl J Med*. 1990; 323: 645-655.

- Lewy JE:** Nephrology ;fluids electrolytes. In: Behrman RE and Kleigman RM (eds).Nelson Essentials of pediat (2<sup>th</sup> ed). WB Saunders Company, Philadelphia, London, Toronto, Sydey, Tokyo.1994; 2: 1313-1450.
- Lianos EA, Bresnahan BA. Pan C:** Mesangial cell immune injury, synthesis, origin and role of eicosanoids. J Clin Invest. 1991;88: 623-631.
- Lianos EA, Bresnahan BB, Wu S:** Pathophysiologic role of eicosanoids in mesangial cell immune injury. J Lipid Mediat. 1993;6:333-342.
- Lianos EA, Noble B, Huckle B:** Glomerular leukotriene synthesis in Heymann nephritis. Kidney Int. 1989;36: 998-1002.
- Lianos EA:** Synthesis of hydroeicosatetranoic acids and leukotrienes in rat nephrotoxic serum nephritis. J Clin Invest. 1988; 82: 427-435.
- Lin, S.-Y. and Riggs, A.D.:** The general affinity of lacpressor for E. coli DNA: implications for gene regulation in prokaryotes and eukaryotes. Cell. 1975. 4: 107-111.
- Ljungberg P, Holmberg C, Jalanko H:** Infections in infants with congenital nephrosis of the finish type. Pediatr Nephrol.1997; 11: 148-152.

- Losick, R. and Stragier, P.:** Crisscross regulation of cell-type specific gene expression during development in *B. subtilis*. *Nature*. 1992; 355: 601-604.
- Makita N, Funk CD, Imai E, Hoover RI, Badr KF:** Molecular cloning and functional expression of rat leukotriene A<sub>4</sub> hydrolase using the polymerase chain reaction. *FEBS Lett*. 1992 ;299: 273-277.
- Manetti R.P, Parronchi M.G, Giudizi M.P, Piccinini E, Maggi G. Trinchieri G, and Romagnani S:** Natural killer cell stimulatory factor (Interleukin-12) induces T helper type 1 (Th<sub>1</sub>)-specific immune responses and inhibits the development of IL<sub>4</sub> producing Th cells. *J Exp Med*. 1993;177: 1199.
- Mannikko M, Kestila M, Lenkkeri V et al.:** Improved prenatal diagnosis of the congenital nephrotic syndrome of finish type by DAN analysis. *Kid Int*. 1997; 51: 868-872.
- Marcus AJ:** Multicellular eicosanoid and other metabolic interactions of platelets and other cells. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. *Hemostasis and thrombosis: basic principles and clinical practice*. Philadelphia: JB Lippincott. 1994;590-602.
- Matsumoto K and Kanmatsuse K:** Increased IL<sub>12</sub> release by monocytes in nephrotic patients. *Clinical Experimental Immunology*. 1999;117: 361-367.

- Matsumoto K, Ohi H, Kanmatsuse K:** Interleukin-13 synergize to inhibit vascular permeability factor release by peripheral Blood Mononuclear cells from patients with lipoid nephrosis. *Nephron*. 1997;77: 212-218.
- Matsumoto K, Osakabe K, katayama H, and Hatano M.:** In vitro lymphocyte dysfunction in lipoid nephrosis mediated by suppressor cells. *Nephron*. 1982; 32:270-272.
- Mayet WJ, Schwarting A, Orth T, Duchmann R:** Antibodies to proteinase 3 mediate expression of vascular cell adhesion molecule-1 (VCAM-1). *Clin Exp Immunol*. 1996;103: 259.
- McEnery PT and Coutinho MJ:** Membrano-proliferative glomerulonephritis. In: Holliday MA, Barratt TM, Avener (eds) *Pediatric Nephrol* 3<sup>th</sup> edition, Williams & Wilkins, Baltimore, pp. 1994;739-753.
- McKusick VA:** History of medical genetics. In Rimoin DL, Connor JM, Pyeritz RE (eds.): *Emery and Rimoin's principles and practice of Medical Genetics*. 3<sup>rd</sup> ed. Vol. 1. Churchill Livingstone, New York. 1997;P1.
- McPherson, C.E., Shim, E.-Y., Friedman, D.S., and Zaret, K.S.:** An active tissue-specific enhancer and bound transcription factors existing in a precisely positioned nucleosomal array. *Cell*. 1993; 75: 387-398.

- McVicar MI, Chandra M, Margoullef D et al.:** Splenic hypofunction in the NS of childhood. *Am J Kid Dis.* 1986;7: 395.
- Mendoza SA, and Tune BM:** Management of the difficult nephrotic patient. *Ped Clin Nor Am.* 1995;42: 1459.
- Mendrick DL and Rennke HG:** Induction of proteinuria in rat by monoclonal antibody 115/107. *Kid Int.* 1988;818-830.
- Menegatti E., D. Roccatello, K. Hadden, G. Piccoli, G. De Rosa, L.M. Sena & A. Rifai:** Gene expression of 5-lipoxygenase and LTA<sub>4</sub> hydrolase in renal tissue of nephrotic syndrome patients. *Clin Exp Immunolgy.* 1999;116: 347-353.
- Meslier N, Aldrich AJ, Bigby TD:** Effect of interferon – gamma on the 5-lipoxygenase pathway of rat lung macrophages. *Am J Respir Cell Mol Biol.* 1992; 6: 93-99.
- Milford DV & Taylor CM:** Prognostic significance of proteinuria in hemolytic uraemic syndrome. *Journal of Pediat.* 1991;118: 191-192.
- Miller JO.:** Chromosomal basis of inheritance. In Rimoin DL, Connor JM, Pyeritz RE, (eds.): *Emery and Rimoin's principles and practice of Medical Genetics.* 3<sup>rd</sup> ed. Vol. 1. Churchill Livingstone, New York. 1997;P235.
- Miller OK, Gillard JW, Vickars PJ, et al.:** Identification and isolation of membrane protein necessary for leukotriene production. *Nature.* 1990;343: 278-281.

- Miller SA, Dykes DD, Polesky HF:** A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acids Res. 1988;16: 1215.
- Milne AAY, Piper PJ:** The leukotriene B<sub>4</sub> antagonist, U-75, 302, inhibits antigen-induced airway hyperresponsiveness but not leukocyte accumulation in sensitized guinea pigs (abstract). B<sub>5</sub>J Pharmacol. 1995;114: 150.
- Minami M, Mutoh H, Ohishi N, Honda Z, Bito H, Shimizo T:** Amino-acid sequence and tissue distribution of guinea -pig leukotriene A<sub>4</sub>hydrolase. Gene. 1995;161: 249-251.
- Moe GW , Legault L and Skorecki KL:** Control of extracellular fluid volume and pathophysiology of edema formation. In: Brenner BM and Rector FC (eds).the Kid 4<sup>th</sup> ed. Philadelphia, WB Saunders.1991;623.
- Mong S, Chi-Rosso G, Miller J, Hoffman K, Razgaitis KA, Bander P, Crooke ST:** Leukotriene B<sub>4</sub> induces formation of inositol phosphates in rat peritoneal polymorphonuclear leukocytes. Mol Pharmacol. 1986;30: 235-242.
- Montero A, Nassar GM, Badr KF.:** Lymphokines and macrophage-derived cytokines regulate leukotriene A<sub>4</sub> hydrolase mRNA expression and LTB<sub>4</sub> production in human monocytes and glomerular mesangial cells (Abstract).J Am Soc Nephrol. 1995;6: 844.

- Montero A., George M, Nassar Susumu Uda, Karen A. Munger and Kamal F. Badr:** Reciprocal regulation of LTA<sub>4</sub> hydrolase expression in human monocytes by  $\gamma$ - interferon and interleukins 4 and 13; Potential relevance to leukotriene regulation in glomerular disease. *Exp Nephrol.* 2000;8: 258-265.
- Morita M, White RHR, Coad NAG:** The clinical significance of the glomerular location of segmental lesion in focal segmental glomerulonephrosclerosis. *Clin Nephrol.* 1990: 33: 211-219.
- Morrow J, Awad J, Kato T, et al.:** Formation of novel non – cyclooxygenase-derived prostanoids (F<sub>2</sub>-isoprostanes) in carbon tetrachloride hepatotoxicity. An animal model of lipid peroxidation. *J Clin Invest.* 1992; 90: 2502-2507.
- Muller F:** Morbus Brightii, Verch Dtch. *Pathol Ges*9: 64. Coated from *Ped Kid Dis.* 1905: 2: 1247-1250 Chester M Edelman (eds).
- Mundel P, Kriz W:** Structure and function of podocyte. An update. *Anat Embryol.* 1995;192: 385-397.
- Munk F:** Klinische Diagnostik der degenerative Nierenkrankungen Et Klein Med. Coated from *Ped Kid Dis.* 1913; 2: 1242-1250 Chester M Edelman (eds).
- Nacchache P11, Faucher N, Therrien S, Borgeat P:** Calcium mobilization, actin polymerization and right-angle light scatter responses to leukotriene B<sub>4</sub>. 12 (R) – and –12 (S)-

- hydroxyeicosaetraenoic acid in human neutrophils. *Life Sci.* 1988;42: 727-733.
- Nadeau JH.:** Modifier genes in mice and humans. *Nat Rev Genet.* 2001;3: 165-174. Review.
- Nash MA, Edelmann CM, Bernstein J:** a-The nephrotic syndrome b- Minimal change nephrotic syndrome In: Edelmann CM (eds). *Pediatric Kidney disease* (2<sup>th</sup> ed) Little , Brown and Company, Boston, Toronto, London. 1992a; 54: 1247-1266.
- Nash MA, Grier I and Obling H:** The significance of focal sclerotic lesions of glomeruli in children. *J Ped.* 1992b; 88: 806.
- Nassar GM, Montero A, Fukunaga M, Badr KF:** Contrasting effects of proinflammatory and T-helper lymphocyte subset-2 cytokines on the 5-lipoxygenase pathway in monocytes. *Kidney Int.* 1997;51: 1520-1528.
- Nassar GM, Morrow JD, Roberts LJ, Lakkis FG, Badr KF:** Induction of 15-lipoxygenase by interleukin -13 in human blood monocytes. *J Biol Chem.* 1994;269: 2763-2785.
- Neuhau TJ, Shah V, Callard RE et al.:** T lymphocyte activation in steroid-sensitive NS. *Childhood Nephrol Dial Transplant.* 1995;10: 1348-1352.
- Neuhaus TJ, Wadhwa M, Callard R, et al.:** Increased IL<sub>2</sub>, IL<sub>4</sub> and interferon-gamma (IFN-gamma) in steroid-sensitive nephrotic. 1995.

- Nevalainen TJ:** Serum phospholipases A<sub>2</sub> in inflammatory diseases. Clin Chem. 1993;39: 2453-2507.
- Niaudet P:** The French society of pediatric nephrology treatment of childhood steroid resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. J Pediat. 1994;125: 891.
- Nudler, E. et al.:** The RNA-DNA hybrid maintains the register of transcription by preventing backtracking of RNA polymerase. Cell. 1997; 89: 33-41.
- Ogata M, Matsumoto T, Kamochi M, et al:** Protective effects of a leukotriene inhibitor and a leukotriene antagonist on endotoxin-induced mortality in carrageenan-pertreated mice. Infect Immun. 1992;60: 2432-2437.
- Orning L, Gierse JK, Fitzpatrick FA:** The bifunctional enzyme leukotriene A<sub>4</sub> hydrolase is an arginine aminopeptidase of high efficiency and specificity. J Biol Chem. 1994;269: 11269-11273.
- Ortiz A, Bustos C, Alonso J et al.:** Involvement of cytokines in the pathogenesis of experimental and human glomerulonephritis. Adv Nephrol. 1994;2: 713-818.
- Palmblad J, Malmsten CJ, Uden AM, Radmark O, Engstedt I, Samuelsson B:** Leukotriene B<sub>4</sub> is a potent and stereo specific stimulator of neutrophil chemotaxis and adherence. Blood. 1981;58: 658-661.

- Palombo JD, Lydon EE, Chen PL, et al.:** Fatty acid composition of lung, macrophage and surfactant phospholipids after short-term enteral feeding with n-3lipids. *Lipids*. 1994;29: 643-649.
- Papayianni A, Serhan CN, Brady HR:** Lipoxin A<sub>4</sub> and B<sub>4</sub> inhibit leukotriene stimulated interactions of human neutrophils and endothelial cells. *J Immunol*. 1996; 2264-2272.
- Papyianni A, Serhan CN, Phillips ML, Rennke HG. Brady HR:** Transcellular biosynthesis of lipoxin A<sub>4</sub> during adhesion of platelets and neutrophils in experimental immune complex glomerulonephritis. *Kidney Int*. 1995;47: 1295-1302.
- Petaja J, Jalanko H, Holmberg C et al.:** Resistance to activated protein C as an underlying cause of recurrent venous thrombosis during relapsing NS. *J Ped*. 1995;127: 103-105.
- Peteric R, Ford- Hutchinson A.:** Inhibition of leukotriene biosynthesis improves renal function in experimental glomerulonephritis. *J Lipid Med*. 1995;11: 231-240.
- Peteric R, Ford-Hutchinson AW:** Elevated cysteinyl leukotriene excretion in experimental glomerulonephritis. *Kidney Int*. 1994;46: 1322-1329.
- Philips D, Watson AR, Collier J:** Distress and radiological investigation of the urinary tract in children. *European Journal of Pediat*. 1996 ;13: 211-234.

- Piper PJ, Samhoun MN. Tippins JR. et al.:** Pharmacological studies on pure SRS-A. SRS and synthetic leukotrienes C<sub>4</sub> and D<sub>4</sub>. In: Piper PJ (ed). SRS-A and leukotrienes. John Wiley, Chichester. 1981;81-101.
- Piper PJ. Letts LG. Samhoun MN. Et al.:** Actions of LTs on vascular and gastrointestinal smooth muscle. In: Samuelsson B and Paoletti R (eds.). Leukotrienes and other lipoxygenase products. Raven Press, New York. 1982; 169-182.
- Pober JS:** Cytokine mediated activation of vascular endothelium. Am J Pathol. 1988 ;133: 426-433.
- Primack WA, Schulman SL, Kaplan BG et al.:** An analysis of the approach to management of childhood NS by pediatric nephrologists. Am J Kid Dis. 1994;23: 524.
- Ptashne M, Gann A.:** Transcriptional activation by recruitment. Nature. 1997; 386: 569-577.
- Radmark O, Haggstrom J:** Properties of leukotriene A<sub>4</sub> hydrolase. Adv Prostaglandin thromboxane. Leukot Res. 1990;20: 35-45.
- Radmark O, Shimizu T, Jornvall H Samuelsson B:** Leukotriene A<sub>4</sub> hydrolase in human leukocytes, Purification and properties. J Biol Chem. 1984;259: 12339-12345.
- Rahman MA, Nakazawa M, Emancipator SN, Dunn MJ:** Increased leukotriene B<sub>4</sub> synthesis in immune injured rat glomeruli. J Clin Invest. 1988 ; 81: 1945-1952.

- Rahman MA, Sauter DC, Young MR:** Effects of dietary fish oil on the induction of experimental membranous nephropathy in the rat. *Lab Invest.* 1991;64: 371-376.
- Rees AJ, Peters DK, Amos N, et al.:** The influence of HLA linked genes on the severity of anti-GBM antibody mediated nephritis. *Kid Int.* 1984;26: 444-450.
- Reiss TF, Bronsky E, Hendeles L , et al.:** MK-0476, a potent leukotriene (LT) D<sub>4</sub> antagonist, inhibits exercise-induced bronchoconstriction in asthmatics at the end of a once daily dosing schedule (abstract). *Am J Respir Crit Care Med.* 1995;151: 377.
- Remuzi G, Bertani T and Schieppali A:** Idiopathic membrane nephropathy. *Lancet.* 1993;342: 1277.
- Rhodes SJ, Chen R, DeMattia GE, et al.:** A tissue-specific enhancer confers Pit-1-dependent morphogen indelibility and autoregulation on the pit-gene. *Genes Dev.* 1993; 7: 913-932.
- Rickwood AMK, Carty HM, Mckendrick S:** Current imaging of childhood UTI prospective study. *British Medical Journal.* 1992;304: 663-665.
- Rifai A., Hideto Sakai and Mitsunori Yagame:** Expression of 5-lipoxygenase and 5-lipoxygenase activation protein in

glomerulonephritis. *Kidney international*. 1993;43: S39, 95-99.

**Rodorf G, Uemura Y, Bonventre JV:** Characterization of phospholipase A<sub>2</sub> (PLA<sub>2</sub>) activity in gerbil brain. Enhanced activities of cytosolic, mitochondrial and microsomal forms after ischemia and reperfusion. *J Neurosci*. 1991; 11: 1829-1836.

**Rosenbaum KN:** Genetics and dysmorphology. In Kelalis PP, King LR, Belman AB: *Clinical Pediatric Urology*. 3<sup>rd</sup> ED. Vol, 1. WB Saunders, Philadelphia. 1992;P244.

**Rovin BH, Lefkowitz JB, Schreiner GF:** Mechanisms underlying the anti-inflammatory effects of essential fatty acid deficiency in experimental glomerulonephritis. Inhibited release of a monocyte chemoattractant by glomeruli. *J Immunol*. 1990;145: 1238-1245.

**Salant DJ, Adler S, Darby C, et al.:** Influence of antigen distribution on the mediation of immunologic glomerular injury. *Kid Int*. 1985; 22: 938-950.

**Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN:** Leukotrienes and lipoxins: structures, biosynthesis and biological effects. *Science*. 1987;237: 1171-1176.

**Savin VJ, Chonko AM, Sharma R, Gunwar S, Sharma M:** Factor present in serum of patients with MCNS or FSGS causes an

immediate increase in glomerular protein permeability in vitro. AM Soc Neph.1990; 1: 567.

**Savin VJ, Sharma R, Sharma M:** Circulating factors associated with increased glomerular permeability to albumin in FSGS. N Eng J Med.1996; 334: 878-883.

**Schnaper HW:** The immune system in minimal change NS. Pediatr Nephrol. 1989;3: 101-110.

**Schreiner GF, Rovin B, Lefkowitz JB:** The anti-inflammatory effects of essential fatty acid deficiency in experimental glomerulonephritis, The modulation of macrophage migration and eicosanoid metabolism. J Immunol. 1989;143: 3192-3199.

**Seahore MR, Wappner RS:** Genetics in Primary care and Clinical Medicine. MASS Publishing Co. 1996; Egypt.

**Serhan CN, Fridovich J, Goetzl EJ, Dunham PB, Weissmann G:** Leukotriene B<sub>4</sub> and phosphatidic acid are calcium ionophores. Studies employing arsenazo 111 in liposomes. J Biol Chem. 1982;257: 4746-4752.

**Serhan CN, Samuelsson B: Lipoxins:** A new series of eicosanoids (biosynthesis, stereo-chemistry, and biological activities). Adv Exp Med Biol. 1988 ;229: 1-14.

**Shalhoub RJ:** Pathogenesis of lipid nephrosis, a disorder of B-cell function. Lancet. 1974; 2: 556.

- Shapiro LJ.:** Human Genetics. In Behrman RE, Kligman RM, Arvin AM (eds.): Nelson Textbook of Pediatrics, 15<sup>th</sup> ed. Vol. 1. WB Saunders, Philadelphia. 1996;P299.
- Skinner R, Cole M, Pearson ADJ, Coulthard MG, Graft AW:** Specificity of pH and osmolality of early morning urine sample in assay distal renal tubular function in children. Results in healthy children. British Medical Journal.1996; 312: 1337-1338.
- Sleem A.:** Study of IL-8 in serum and lymphocyte culture of patients with PNS in children. A thesis submitted for MSc degree in pediatrics. 1998.
- Smith WL.:** The eicosanoids and their biochemical mechanisms of action. Biochem J. 1989: 259:315-324.
- Sprague RS, Stephenson AH, Dahms TE, et al:** Proposed role for leukotrienes in the pathophysiology of multiple systems organ failure. Crit Care Clin. 1989;5: 315-329.
- Stefanovic V, Golubovic E, Zalatkovc MM, Vljajovic P, Jovanovic, O and Bogdanovic R.:** Pediatric Nephrology.1997;12: 463-466.
- Strek ME, Solway J, Saller L, Kowash K, Miller CJ, Israel E.:** Effect of the 5- lipoxygenase inhibitor, ZD2138, on cold – air – induced bronchoconstriction in patients with asthma [abstract ]. Am J Respir Crit Care Med. 1995; 151: A 377.

- Suranyi MG, Guasch A, Hall BM, Myers BD:** Elevated levels of tumour necrosis factor alpha in NS in human. *Am J Kid Dis.*1993; 21: 251-259.
- Sutton WS.:** The chromosomes in heredity. *Biol Ball* 4: 321 coated from Mckusick VA(1997): *History of Medical Genetics*. In Rimoin DL, Connor JM, Pyeritz RE(eds.): *Emery and Rimoin's principles and practice of Medical Genetics*. 3<sup>rd</sup> ed. Vol. 1. Churchill Livingstone, New York, 1993;P1.
- Takahashi K, Hato T, Schreiner GF, Ebert J, Badr KF.:** Essential fatty acid deficiency normalizes function and histology in rat nephrotoxic serum nephritis. *Kidney Int.* 1992;41: 1245 – 1253.
- Takata S, Matsubara M, Allen PG, Janmey PA, Serhan CN, Brady HR:** Remodeling of neutrophil phospholipids with 15 (S)-hydroxyeicosatetraenoic acid inhibits leukotriene B<sub>4</sub> – induced neutrophil migration across endothelium. *J Clin Invest.* 1994;93: 499-508.
- Takeda A, Malsutani H, Niimura F et al.:** Risk factors for relapse in childhood nephrotic syndrome. *Pediat Nephrol.* 1996; 10: 740.
- Tanaka R, Yoshika N and Nakamura H:** Infusion of peripheral blood mononuclear cells products from nephrotic children increases albuminuria in rats. *Nephron.* 1992;60: 35-41.

- Tanaka R, Yoshikawa N, Nakamura H, et al:** Infusion of peripheral blood mononuclear cell products from nephritic children increases albuminuria in rats. *Nephron*.1982; 60:35-41.
- Tarshish P, Tobin JN, Bernstein J:** Prognostic significance of early course of FSGS nephrotic syndrome, report of the international study of kidney disease in children. *J Am Soc Nephrol*. 1997;8: 769-776.
- Taube D, Brown Z, and Williams D.G.:** Long term impairment of suppressor cell function by cyclophosphamide in minimal change nephropathy and its association with therapeutic response. *Lancet*. 1981;235-238.
- Taylor GM, Neuhaus TJ, Shah V et al.:** Charge and size selectivity of proteinuria in children with idiopathic NS. *Pediatr Nephrol*. 1997; 11: 404-410.
- Taylor RK, Kevin MO, Richard WF, Colin TO.:** Effect of cysteinyl-leukotriene receptor antagonist ICI 204-219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. *Lancet*. 1991; 337: 690-694.
- Tjio JH, Levan A:** The chromosome number in man. *Hereditas* 42: 1. Coated from McKusick VA(1997): History of medical genetics. In Rimoin DL, Connor JM, Pyeritz RE(eds.): Emery and Rimoin's principles and practice of Medical Genetics. 3<sup>rd</sup> ed. Vol. Churchill Livingstone, New York, P 1.

- Tomesett A and Watson AR:** Renal biopsy as a day case procedure. Pediatric Nursing. 1996; 8: 14-15.
- Truss, M., Barstch, J., Schelbert, A., Hache, R.J.C., and Beato, M.:** Hormone induces binding of receptors and transcription factors to a rearranged nucleosome on the MMTV promoter in vivo. EMBO J. 1994; 14: 1737-1751.
- Tune BM, Kirpekar R, Sibley RK, et al.:** Intravenous methylprednisolone and oral alkalyting agent therapy of prednisone resistant pediatric focal segmental glomerulosclerosis. Long term follow up. Clin Nephrol. 1995; 43: 84.
- Tupler R, Perini G, Green MR.:** Expressing the human genome. Nature. 2001; 409: 822-823.
- Ueda N, Kunok, Ito S, et al.:** Eight and twelve weeks courses of cyclophosphamide in NS. Arch Dis Child. 1990; 65: 1147.
- Uhl, W, Buchler M, Nevalainen TJ, et al:** Serum phospholipase A<sub>2</sub> in patients with multiple injuries. J Trauma. 1990;30: 1285-1290.
- Ullrich V, Haurand M:** Thromboxane synthase as a cytochrome P450 enzyme. Adv Prostaglandin Thromboxane Leukotrienes Res. 1983;11: 105-110.
- Vadas P, Pruzanski W:** Induction of group II phospholipase A<sub>2</sub> expression and pathogenesis of the sepsis syndrome. Circ Shock. 1993;39: 160-167.

- Virchow JC, Noller PS, Wiessman KJ, et al:** Multicenter trial of Bay x 1005, a new 5- lipoxygenase activating protein inhibitor in the treatment of chronic asthma (abstract). Am J Respir Crit Care Med. 1995; 151: A377.
- Waite M.:** The phospholipases, In: Handbook of lipid research. New York: Plenum Press: 1987; 5-27.
- Waldman TA:** The interleukin -2 receptor. J Biol. Chem. 1991; 266:2665-2681.
- Wang, D. et al.:** Discontinuous movements of DNA and RNA in RNA polymerase accompany formation of a paused transcription complex. Cell. 1995; 81: 341-350.
- Watson JD, Crick FHC.:** Molecular structure of nucleic acids; A structure for deoxyribose nucleic acid. Nature. 1953;171: 737.
- Wheeler De and Bernard DB:** lipid abnormalities in the NS. Am J Kid Dis. 1994;23-331.
- White RHR:** The familial nephrotic syndrome. I A European survey Clin Nephrol. 1973;1-215-219.
- Wingen AM, Mullen. W.feel DE , Sharen K et al.:** Spontaneous remission in frequently relapsing and steroid dependent idiopathic NS. Clin Nephro. 1985;12: 23-35.
- Wux, Pippin J, Lefkowitz JB.:** Platelets and neutrophils are critical to the enhanced glomerular arachidonate metabolism in acute nephrotoxic nephritis in rats. J Clin Invest. 1993;91: 766-773.

- Yared A, Albrightson –Winslow C, Griswold D, Takahashi K, Fogo A, Badr KF.:** Functional significance of leukotriene B<sub>4</sub> in normal and glomerulonephritic kidneys. J Am Soc Nephrol. 1991;2: 45-56.
- Yokomizo T, Isumi T, Chang K, et al.:** A G-protein-coupled receptor for leukotriene B<sub>4</sub>, that mediates chemotaxis. Nature. 1997 ; 388: 678.
- Yoshikawa D, Goto F:** Effect of platelet-activating factor antagonist and leukotriene antagonist on endotoxin shock in the rat; Role of the leukocyte. Circ Shock. 1992;38: 29-33.
- Zieste R, Wenting GT, Karmen P et al.:** Glomerular barrier dysfunction in NS. Clin Sci.1992; 82: 641-650.